| 臺大學術典藏 |
2021-07-03T03:33:20Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-04T08:33:28Z |
Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways
|
Chen P.-H.; Peng C.-Y.; Pai H.-C.; Teng C.-M.; Chen C.-C.; CHIA-RON YANG |
| 臺大學術典藏 |
2021-06-04T03:09:24Z |
Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult
|
Yeh T.-C.; Chiang P.-C.; Li T.-K.; Hsu J.-L.; CHUN-JUNG LIN; Wang S.-W.; Peng C.-Y.; Guh J.-H. |
| 臺大學術典藏 |
2021-06-02T05:44:10Z |
Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats
|
Pan S.-L.; Huang Y.-W.; JIH-HWA GUH; Chang Y.-L.; Peng C.-Y.; Teng C.-M. |
| 臺大學術典藏 |
2021-06-02T05:44:05Z |
The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury
|
Peng C.-Y.; Pan S.-L.; JIH-HWA GUH; Liu Y.-N.; Chang Y.-L.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. |
| 臺大學術典藏 |
2021-06-02T05:44:03Z |
YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models
|
Pan S.-L.; JIH-HWA GUH; Peng C.-Y.; Wang S.-W.; Chang Y.-L.; Cheng F.-C.; Chang J.-H.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. |
| 臺大學術典藏 |
2021-06-02T05:44:03Z |
A potential role of YC-I on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models
|
Pan S.-L.; JIH-HWA GUH; Peng C.-Y.; Chang Y.-L.; Cheng F.-C.; Chang J.-H.; Kuo S.-C.; Lee F.-Y.; Teng C.-H. |
| 臺大學術典藏 |
2021-06-02T05:44:01Z |
YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9
|
Liu Y.-N.; Pan S.-L.; Peng C.-Y.; JIH-HWA GUH; Huang D.-M.; Chang Y.-L.; Lin C.-H.; Pai H.-C.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. |
| 臺大學術典藏 |
2021-06-02T05:43:59Z |
Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult
|
Yeh T.-C.; Chiang P.-C.; Li T.-K.; Hsu J.-L.; Lin C.-J.; Wang S.-W.; Peng C.-Y.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-06-02T05:43:58Z |
CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression
|
Wang S.-W.; Pan S.-L.; Peng C.-Y.; Huang D.-Y.; Tsai A.-C.; Chang Y.-L.; JIH-HWA GUH; Kuo S.-C.; Lee K.-H.; Teng C.-M. |
| 臺大學術典藏 |
2021-06-02T05:43:55Z |
YC-1 induces heat shock protein 70 expression and prevents oxidized LDL-mediated apoptosis in vascular smooth muscle cells
|
Liu Y.-N.; Pan S.-L.; Peng C.-Y.; Huang D.-Y.; JIH-HWA GUH; Kuo S.-C.; Lee F.-Y.; Teng C.-M. |
| 臺大學術典藏 |
2021-06-02T05:43:54Z |
Baicalein attenuates intimal hyperplasia after rat carotid balloon injury through arresting cell-cycle progression and inhibiting ERK, Akt, and NF-κB activity in vascular smooth-muscle cells
|
Peng C.-Y.; Pan S.-L.; Huang Y.-W.; JIH-HWA GUH; Chang Y.-L.; Teng C.-M. |
| 臺大學術典藏 |
2021-06-02T05:43:53Z |
Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1α accumulation in RAW264.7
|
Liu Y.-N.; Pan S.-L.; Liao C.-H.; Huang D.-Y.; JIH-HWA GUH; Peng C.-Y.; Chang Y.-L.; Teng C.-M. |
| 臺大學術典藏 |
2021-06-02T05:43:52Z |
Moscatilin repressed lipopolysaccharide-induced hif-1α accumulation and NF-κB activation in murine raw264.7 cells
|
Liu Y.-N.; Pan S.-L.; Peng C.-Y.; Huang D.-Y.; JIH-HWA GUH; Chen C.-C.; Shen C.-C.; Teng C.-M. |
| 臺大學術典藏 |
2021-06-02T05:43:50Z |
The indazole derivative YD-3 specifically inhibits thrombin-induced angiogenesis in vitro and in vivo
|
Peng C.-Y.; Pan S.-L.; Pai H.-C.; Tsai A.-C.; JIH-HWA GUH; Chang Y.-L.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. |
| 臺大學術典藏 |
2021-05-31T05:59:15Z |
Genetic analysis of age-dependent defects of the Caenorhabditis elegans touch receptor neurons
|
CHUN-LIANG PAN; Peng C.-Y.; Chen C.-H.; McIntire S. |
| 臺大學術典藏 |
2021-05-24T07:20:43Z |
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
|
Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; Su T.-H.; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; CHEN-HUA LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:29Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; CHEN-HUA LIU; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2021-05-24T07:20:26Z |
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan
|
CHEN-HUA LIU; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:24Z |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
|
Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; CHEN-HUA LIU; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; Kao J.-H.; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-05-24T07:20:23Z |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
|
CHEN-HUA LIU; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:21Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
CHEN-HUA LIU; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:20Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
CHEN-HUA LIU; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:19Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; CHEN-HUA LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:19Z |
Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis
|
Su T.-H.; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; CHEN-HUA LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:18Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
CHEN-HUA LIU; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:18Z |
2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population
|
Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. |
| 臺大學術典藏 |
2021-05-24T07:20:17Z |
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; Liu C.-J.; CHEN-HUA LIU; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2021-05-24T07:20:17Z |
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
|
Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. |
| 臺大學術典藏 |
2021-05-24T07:20:16Z |
Successful antiviral therapy reduces risk of schizophrenia among chronic hepatitis c patients: A nationwide real-world Taiwanese cohort (T-COACH)
|
Tsai P.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Kao J.-H.; Liu C.-J.; CHEN-HUA LIU; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Hsieh M.-H.; Huang J.-F.; Dai C.-Y.; Chung W.-L.; Ke C.-L.K.; Yu M.-L.; T-COACH Study Group |
| 臺大學術典藏 |
2021-05-24T07:20:14Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
CHEN-HUA LIU; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:14Z |
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis
|
Hsu W.-F.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; Liu C.-J.; CHEN-HUA LIU; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Tsai P.-C.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. |
| 臺大學術典藏 |
2021-05-24T07:20:13Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
CHEN-HUA LIU; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?�Y.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:13Z |
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
|
Hsieh M.-H.; Bair M.-J.; Tsai P.-C.; Tseng K.-C.; Lo C.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Kao J.-H.; Liu C.-J.; CHEN-HUA LIU; Yan S.-L.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Yu M.-L.; Chuang W.-L.; T-COACH investigators |
| 臺大學術典藏 |
2021-05-24T07:20:12Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU; Lee M.-H.; Liu C.-J.; Dai C.-Y.; Kao J.-H.; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2021-05-06T01:25:13Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; CHIEN-CHING HUNG; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-29T07:24:26Z |
Multimode VCSEL Enables Multi-Data-Format Encoding up to 124 Gbit/s
|
Lo, W.-C.; Wu, W.-L.; Peng, C.-Y.; Wang, H.-Y.; Tsai, C.-T.; Su, B.; Wu, C.-H.; Lin, G.-R.; GONG-RU LIN |
| 臺大學術典藏 |
2021-03-29T07:24:26Z |
Multimode VCSEL Enables 42-GBaud PAM-4 and 35-GBaud 16-QAM OFDM for 100-m OM5 MMF Data Link
|
Huang, C.-Y.; Wang, H.-Y.; Peng, C.-Y.; Tsai, C.-T.; Wu, C.-H.; Lin, G.-R.; GONG-RU LIN |
| 臺大學術典藏 |
2021-03-09T01:47:44Z |
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
|
Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; TUNG-HUNG SU; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:43Z |
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
|
Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; TUNG-HUNG SU; Tseng T.-C.; Hsu C.-S.; Lin H.H.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:38Z |
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
|
Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; TUNG-HUNG SU; Tseng T.-C.; Lin H.H.; Wang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:33Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; TUNG-HUNG SU; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:32Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
TUNG-HUNG SU; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-03-09T01:43:16Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; TUNG-HUNG SU; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:14Z |
Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis
|
TUNG-HUNG SU; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:14Z |
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy
|
Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; TUNG-HUNG SU; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; Kao J.-H.; Yuen M.-F.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2021-03-09T01:43:13Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; TUNG-HUNG SU; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:12Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; TUNG-HUNG SU; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:09Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; TUNG-HUNG SU; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-02-02T02:48:04Z |
Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients
|
Kao J.-T.; Lai H.-C.; Tsai S.-M.; Lin P.-C.; Chuang P.-H.; Yu C.-J.; Cheng K.-S.; Su W.-P.; PING-NING HSU; Peng C.-Y.; Wu Y.-Y. |
